Pfizer, BioNTech COVID Vaccine Wins European Backing

December 22, 2020by Naomi Kresge and Suzi Ring, Bloomberg News (TNS)
Pfizer, BioNTech COVID Vaccine Wins European Backing

Pfizer Inc. and BioNTech SE’s COVID-19 vaccine won the backing of the European medicines regulator, clearing the way for inoculations to start before the end of the year as the continent struggles with rising death rates and tighter lockdowns.

The endorsement of the vaccine, Comirnaty, was announced in a news briefing by the European Medicines Agency on Monday. The final step in approval is a sign-off from the European Commission, expected later today.

“It is a significant step forward in our fight against this pandemic,” Emer Cooke, executive director of the agency, said in the meeting. “This is really a historic scientific achievement.”

EMA officials said there’s no evidence to suggest the vaccine won’t work against the new variant of the coronavirus that emerged in southeast England, leading to an emergency lockdown in London and causing countries including Canada, France and Germany to halt flights and suspend rail links.


European Union leaders pushed the regulator to speed up its review amid complaints that residents across the continent were still waiting to get a vaccine — pioneered in Germany — that is already being used in the U.K. and U.S. The goal is to start a European immunization campaign on Dec. 27, commission President Ursula von der Leyen said last week.

Monday’s recommendation puts the EU in position to meet that timeline. Von der Leyen said in a tweet that she expects the commission to act swiftly, with a decision by tonight.


The trials showed the vaccine was effective in preventing Covid-19 in people from 16 years of age, the agency said in a statement.

Just as Europe prepares to roll out the first vaccine, countries are suspending travel links to the U.K. amid an effort to contain a variant of the coronavirus that officials say is spreading quickly across London and southeast England.

Unlike the U.S. and U.K., which conducted emergency authorizations, the EMA reviewed the vaccine for a conditional marketing authorization. Such a decision requires more evidence, the EU commission’s directorate-general for health said last week. The EMA committee is also reviewing a similar vaccine from Moderna Inc., with a key meeting set for Jan. 6.

___


©2020 Bloomberg L.P.

Distributed by Tribune Content Agency, LLC

A+
a-

In The News

Health

Voting

Health

Abortion Rights Groups Look to Next Fights After 2022 Wins

CHICAGO (AP) — Emboldened by the results of November's midterms, abortion rights supporters say they are preparing for even bigger fights... Read More

CHICAGO (AP) — Emboldened by the results of November's midterms, abortion rights supporters say they are preparing for even bigger fights in state legislatures and pivotal elections to come, including 2024 races for Congress and president. Victories for abortion rights ballot measures and candidates who support abortion provided a... Read More

November 30, 2022
by Dan McCue
GOP Senators Oppose Advancing NDAA Unless Military Vaccine Mandate Canned

WASHINGTON — A group of U.S. senators led by Sens. Rand Paul, R-Ky., and Lindsey Graham, R-S.C., said they will... Read More

WASHINGTON — A group of U.S. senators led by Sens. Rand Paul, R-Ky., and Lindsey Graham, R-S.C., said they will oppose passage of this year’s defense spending authorization unless the chamber votes to repeal the current COVID-19 vaccine mandate for military personnel. In a letter to... Read More

November 30, 2022
by Dan McCue
Initiative Makes $350M Available to Increase COVID-19 Vaccinations

WASHINGTON — The Biden administration is making $350 million available to increase COVID-19 vaccinations at Health Resources and Services Administration-supported... Read More

WASHINGTON — The Biden administration is making $350 million available to increase COVID-19 vaccinations at Health Resources and Services Administration-supported health facilities. The funding will support health centers administering updated COVID-19 vaccines through mobile, drive-up, walk-up or community-based vaccination events, including working with community-based organizations and... Read More

November 30, 2022
by Dan McCue
WHO Recommends New Name for Monkeypox Disease

GENEVA — The World Health Organization has begun using the term “mpox” as the preferred synonym for monkeypox. Both names... Read More

GENEVA — The World Health Organization has begun using the term “mpox” as the preferred synonym for monkeypox. Both names will be used simultaneously for one year while “monkeypox” is phased out, the organization said. According to the WHO, when the current outbreak of monkeypox began... Read More

November 30, 2022
by Dan McCue
WHO Urges More Effective Prevention of Injuries and Violence

GENEVA —The statistics are sobering. One in 12 deaths worldwide are caused by some form of injury and/or violence, and... Read More

GENEVA —The statistics are sobering. One in 12 deaths worldwide are caused by some form of injury and/or violence, and when all those deaths are tallied, the outcome shows that traffic accidents, drownings, falls, burns and suicides are taking the lives of some 12,000 people a... Read More

November 30, 2022
by TWN Staff
New Study Challenges ‘Good’ Cholesterol’s Role in Predicting Heart Disease Risk

BETHESDA, Md. — A new study has found that high-density lipoprotein cholesterol, the so-called "good cholesterol," may not be as... Read More

BETHESDA, Md. — A new study has found that high-density lipoprotein cholesterol, the so-called "good cholesterol," may not be as effective as scientists once believed in uniformly predicting cardiovascular disease risk among adults of different racial and ethnic backgrounds.  In fact, the research, which was supported... Read More

News From The Well
scroll top